January 23, 2018 / 9:22 PM / 8 months ago

BRIEF-Cerus - Chronic Anemia Phase 3 Study Met Primary Efficacy And Safety Endpoints

Jan 23 (Reuters) - Cerus Corp:

* CERUS REPORTS POSITIVE TOP-LINE RESULTS FROM CHRONIC ANEMIA PHASE 3 STUDY EVALUATING INTERCEPT RED BLOOD CELLS IN THALASSEMIA PATIENTS

* CERUS CORP - STUDY SUCCESSFULLY MET PRIMARY EFFICACY AND SAFETY ENDPOINTS

* CERUS CORP - FULL RESULTS OF STUDY ARE PLANNED FOR SUBMISSION AND PRESENTATION AT UPCOMING SCIENTIFIC CONFERENCES AND FOR PUBLICATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below